CLEFF4 cell line

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

• Name: CLEFF4 cell line
• Research fields: Drug development
• Parental cell: Caco-2
• Organism: Human
• Tissue: Colon
• Model: Mutant
• Description: Pharmaceutical drug development requires drug targets to be characterised against efflux transporters. An example is P-glycoprotein (P-gp) which prevents the uptake and trans-cellular transport of hundreds of drug groups. The standard model is to use Caco-2 cells as these can be induced to express high concentrations of P-gp. Said tight junction model can approximate the role of P-gp at the barrier sites in the body including the gastrointestinal tract and also the blood-brain-barrier. There are however limitations to the Caco-2 cell line, including taking 24 days to develop the characteristics required for P-gp-mediated efflux modelling. Further, other efflux proteins including BCRP and MRP2 are often present in Caco-2 cells, which add extra variables when characterising specific P-gp mediated effects. The CLEFF4 cell line is ready to use in just 5 days and has a 3-fold higher expression of P-gp cells at 5-7 days compared to Caco-2 cells at day 21, expressing no more MRP2 and less BCRP than the parent Caco-2 cells. This is a faster, more specific model for P-gp assays offering cost and time savings and which has reduced medium requirement (one can use standard not accelerated media).

Target Details

• Target: CLEFF4

Handling

• Format: Frozen
• Unit size: 1x10^6 cells / vial
• Shipping conditions: Dry ice

References

• Andrew Crowe. 2024. Eur J Pharm Biopharm. 199:114291. PMID: 38641230.
• Andrew Crowe. 2021. SLAS Discov. 26(1):151-160. PMID: 32706283.